BiotechTube
Shift Bioscience

Shift Bioscience

Cambridge, United Kingdom· Est.
shiftbioscience.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $2M

Overview

Shift Bioscience is an early-stage biotech pioneering an AI-powered approach to cellular rejuvenation, aiming to treat age-related diseases by reversing epigenetic aging signatures. Its core technology platform identifies gene targets that safely reverse aging clocks, with a lead program (SB000) targeting age-related hearing loss and a pipeline exploring liver fibrosis and systemic sclerosis. The company operates from Cambridge, UK, and Toronto, Canada, positioning itself at the intersection of computational biology and traditional therapeutic development to address the fundamental biology of aging.

Age-related Hearing LossLiver FibrosisSystemic Sclerosis

Technology Platform

AI-driven platform integrating proprietary single-cell aging clocks and virtual cell models to discover and validate single-gene targets for safe cellular rejuvenation, decoupling age reversal from changes in cell identity and oncogenic risk.

Funding History

1
Total raised:$2M
Seed$2M

Opportunities

The aging population creates a vast, growing market for therapies that address the root cause of chronic diseases.
Shift's targeted approach to specific, high-need indications like hearing loss and fibrosis offers a potentially faster regulatory path.
Its AI platform could generate a sustainable pipeline of novel targets, creating significant value through internal programs and potential partnerships.

Risk Factors

The core science of safe cellular rejuvenation is unproven, with significant biological uncertainty and potential for serious safety issues like tumorigenesis.
The AI/ML platform's predictions require extensive and costly wet-lab validation.
As a pre-revenue, private company, it faces high financing risk and intense competition from other well-funded longevity biotechs.

Competitive Landscape

Shift competes in the emerging longevity biotech space against companies like Altos Labs, Retro Biosciences, and Life Biosciences, which also pursue cellular reprogramming. Its differentiation lies in its focus on single-gene targets (vs. multi-factor cocktails like OSKM) and its integrated AI/ML platform for discovery. It also faces potential competition from large pharma companies investing in aging biology and fibrosis/hearing loss specialists.

More companies in United Kingdom →